Southeast Asia Nations Vie For Share Of Outsourcing Explosion
This article was originally published in PharmAsia News
The struggle by six countries in Southeast Asia to be leaders in the global outsourcing market for drug development and discovery has intensified. China, India, Japan, Singapore, South Korea and Thailand are vying for a greater share of the $37.1 billion pharmaceutical and biotech outsourcing market. The market is expected to grow by another $11 billion by the end of the year. Every major Asian country is in a race to get a greater share. (Click here for more
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.